82
Participants
Start Date
May 31, 2005
Primary Completion Date
May 31, 2009
Study Completion Date
May 31, 2009
Atorvastatin
atorvastatin at the dose of 80 mg/day. Participants will be allowed to decrease the daily dose to 40 mg/day if the higher dose is not well-tolerated
Placebo
tablet form
Mount Sinai School of Medicine, New York
Jacobs Neurological Institute, Buffalo
University of Rochester, Rochester
Johns Hopkins, Baltimore
Cleveland Clinic Foundation, Cleveland
Washington University Multiple Sclerosis Center, St Louis
University of Texas Southwestern Medical Center, Dallas
Barrow Neurological Institute, Phoenix
Keck School of Medicine, Los Angeles
University of California, San Francisco, San Francisco
Oregon Health Sciences University, Portland
Virginia Mason MS Center, Seattle
Yale MS Research Center, New Haven
Montreal Neurological Institute, Montreal
Immune Tolerance Network (ITN)
NETWORK
National Institute of Allergy and Infectious Diseases (NIAID)
NIH